Skip to main content

Table 1 Clinical and Pathological features of ovarian cancer patients according to deleterious BRCA1/2 mutations

From: Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil

  BRCA 1/2 mut BRCA1/2 wt
n = 19 n = 81
Age at diagnosis, median (range), years 54 (39–63) 55 (33–81)
Time between diagnosis and inclusion (months) 23.33 ± 14.53 19.83 ± 13.52
Histology, n (%)
 Serous 18 (94.7) 66 (81.5)
 Non-serous 1 (5.3) 15 (18.5)
Clinical Stage, n (%)
 I/II 0 (0) 21 (25.9)
 III/IV 19 (100) 59 (72.8)
 Missing 0 (0) 1 (1.2)
Region of origin, n (%)
 Southeast 9 (47.4) 48 (59.3)
 Northeast 7 (36.8) 21 (25.9)
 South 2 (10.5) 8 (9.9)
 North 1 (5.3) 1 (1.2)
 Abroad 0 (0) 2 (2.4)
 Missing 0 (0) 1 (1.2)
Ancestry until 3rd degree, n (%)
 Brazilian only 7 (36.8) 31 (38.3)
 European only 2 (10.5) 12 (14.8)
 Japanese only 1 (5.3) 4 (4.9)
 Asian only 0 (0) 1 (1.2)
 Brazilian and European 5 (26.3) 16 (19.8)
 Brazilian and Indigenous 2 (10.5) 1 (1.2)
 Indigenous and European 0 (0) 1 (1.2)
 Indigenous and Brazilian and European 2 (10.5) 1 (1.2)
 Brazilian and African 0 (0) 2 (2.5)
 Brazilian and African and European 0 (0) 1 (1.2)
 Brazilian and Japanese 0 (0) 2 (2.5)
 Unknown 0 (0) 8 (9.9)
 Missing 0 (0) 1 (1.2)
Family history for breast and/or ovarian cancer
 Positive (first and/or second-degree relatives) 11 (57.9) 20 (24.7)
 Negative 5 (26.3) 32 (39.5)
 Not Completely Known/Unknown 3(15.8) 29 (35.8)